Treatment

Multiple System Atrophy

Volumn , Issue , 2014, Pages 169-194

  Fanciulli, Alessandra ^a,b   Wenning, Gregor K ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920968119     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0687-7_10     Document Type: Chapter

References (125)

1. Abrams P, Cardozo L, Wein A (2011) The 2nd International Consultation on Incontinence, Research Society (ICI-RS) meeting 2010. Neurourol Urodyn 30:683
2. Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T, Holton JL (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38:4-24
3. Ajo R, Cacicedo L, Navarro C, Sanchez-Franco F (2003) Growth hormone action on proliferation and differentiation of cerebral cortical cells from fetal rat. Endocrinology 144:1086-1097
4. Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, Biaggioni I (2013) Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension 61:701-706
5. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM (1997) Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord 12:946-951
6. Azher SN, Jankovic J (2005) Camptocormia: pathogenesis, classification, and response to therapy. Neurology 65:355-359
7. Beck RO, Betts CD, Fowler CJ (1994) Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 151:1336-1341
8. Benarroch EE, Schmeichel AM, Low PA, Parisi JE (2004) Involvement of medullary serotonergic groups in multiple system atrophy. Ann Neurol 55:418-422
9. Benrud-Larson LM, Sandroni P, Schrag A, Low PA (2005) Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 20:951-957
10. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132:156-171
11. Boesch SM, Wenning GK, Ransmayr G, Poewe W (2002) Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 72:300-303
12. Boeve BF, Silber MH, Ferman TJ (2003) Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4:281-284
13. Chitose S, Kikuchi A, Ikezono K, Umeno H, Nakashima T (2012) Effect of laser arytenoidectomy on respiratory stridor caused by multiple system atrophy. J Clin Sleep Med 8:713-715
14. Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D (1979) Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 301:68-73
15. Colosimo C, Merello M, Pontieri FE (1996) Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. J Neurol 243:422-425
16. Colosimo C, Morgante L, Antonini A, Barone P, Avarello TP, Bottacchi E, Cannas A, Ceravolo MG, Ceravolo R, Cicarelli G, Gaglio RM, Giglia L, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, del Dotto P, Simoni L, Marconi R (2010) Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 257:5-14
17. Dasgupta P, Haslam C, Goodwin R, Fowler CJ (1997) The ‘Queen Square bladder stimulator’: a device for assisting emptying of the neurogenic bladder. Br J Urol 80:234-237
18. de Seze MP, Creuze A, de Seze M, Mazaux JM (2008) An orthosis and physiotherapy programme for camptocormia: a prospective case study. J Rehabil Med 40:761-765
19. Djaldetti R, Mosberg-Galili R, Sroka H, Merims D, Melamed E (1999) Camptocormia (bent spine) in patients with Parkinson’s disease-characterization and possible pathogenesis of an unusual phenomenon. Mov Disord 14:443-447
20. Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Doring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Kollensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Bottger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25:97-107
21. Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1176-1177
22. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schupbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH (2013) Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol 20:5-15
23. Fetoni V, Soliveri P, Monza D, Testa D, Girotti F (1999) Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 66:541-544
24. Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, Holmes J, Kingdom WK, Macmahon DG, Peto V, Playfer JR (2003) Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord 18:1139-1145
25. Flabeau O, Meissner WG, Tison F (2010) Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord 3:249-263
26. Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, Valente KD, Pascual-Leone A, Marcolin MA (2004) Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1171-1174
27. Friess E, Kuempfel T, Modell S, Winkelmann J, Holsboer F, Ising M, Trenkwalder C (2006) Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 12:432-437
28. Gazulla J, Benavente MI (2005) Improvements in the symptoms of olivopontocerebellar atrophy with gabapentin. Rev Neurol 40:285-288
29. Gerton BK, Theeler B, Samii A (2010) Backpack treatment for camptocormia. Mov Disord 25:247-248
30. Ghorayeb I, Bioulac B, Tison F (2004) Relationship between stridor and sleep apnoea syndrome: is it as simple as that? J Neurol Neurosurg Psychiatry 75:512-513, author reply 513
31. Ghorayeb I, Yekhlef F, Bioulac B, Tison F (2005) Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Med 6:359-362
32. Giannantoni A, Rossi A, Mearini E, del Zingaro M, Porena M, Berardelli A (2009) Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol 182:1453-1457
33. Gilman S, May SJ, Shults CW, Tanner CM, Kukul! W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T (2005) The North American Multiple System Atrophy Study Group. J Neural Transm 112:1687-1694
34. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670-676
35. Goetz CG, Tanner CM, Klawans HL (1984) The pharmacology of olivopontocerebellar atrophy. Adv Neurol 41:143-148
36. Goldstein DS (ed) (2006) Adrenalin and the inner world. An introduction to scientific integrative medicine. The John Hopkins University Press, Baltimore.
37. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U (2002) Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov Disord 17:1213-1220
38. Harms MP, Wieling W, Colier WN, Lenders JW, Secher NH, van Lieshout JJ (2010) Central and cerebrovascular effects of leg crossing in humans with sympathetic failure. Clin Sci (Lond) 118:573-581
39. Heo JH, Lee ST, Chu K, Kim M (2008) The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci 271:87-90
40. Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C, Tolosa E, Cardozo A, Dizdar N, Rascol O, Slaoui T (2007) Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 22:1138-1144
41. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71:371-374
42. Iranzo A (2005) Management of sleep-disordered breathing in multiple system atrophy. Sleep Med 6:297-300
43. Iranzo A, Santamaria J, Tolosa E, Vilaseca I, Valldeoriola F, Marti MJ, Munoz E (2004) Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 63:930-932
44. Iranzo A, Santamaria J, Rye DB, Valldeoriola F, Marti MJ, Munoz E, Vilaseca I, Tolosa E (2005) Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 65:247-252
45. Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63:43-52
46. Ito T, Sakakibara R, Yasuda K, Yamamoto T, Uchiyama T, Liu Z, Yamanishi T, Awa Y, Yamamoto K, Hattori T (2006) Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 21:816-823
47. Jain S, Dawson J, Quinn NP, Playford ED (2004) Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 19:1360-1364
48. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM (1993) Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95:38-48
49. Jansen RW, Connelly CM, Kelley-Gagnon MM, Parker JA, Lipsitz LA (1995) Postprandial hypotension in elderly patients with unexplained syncope. Arch Intern Med 155:945-952
50. Jin K, Okabe S, Chida K, Abe N, Kimpara T, Ohnuma A, Nomura H, Itoyama Y, Onodera H (2007) Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology 68:1618-1621
51. Kay GG, Ebinger U (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62:1792-1800
52. Kikuchi A, Takeda A, Okamura N, Tashiro M, Hasegawa T, Furumoto S, Kobayashi M, Sugeno N, Baba T, Miki Y, Mori F, Wakabayashi K, Funaki Y, Iwata R, Takahashi S, Fukuda H, Arai H, Kudo Y, Yanai K, Itoyama Y (2010) In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxa-zole positron emission tomography in multiple system atrophy. Brain 133:1772-1778
53. Kleiner-Fisman G, Fisman DN, Kahn FI, Sime E, Lozano AM, Lang AE (2003) Motor cortical Stimulation for parkinsonism in multiple system atrophy. Arch Neurol 60:1554-1558
54. Kohl Z, Winner B, Ubhi K, Rockenstein E, Mante M, Munch M, Barlow C, Carter T, Masliah E, Winkler J (2012) Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. Eur J Neurosci 35:10-19
55. Kollensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, del Sorbo F, Albanese A, Gurevich T, Giladi N, Djaldetti R, Schrag A, Low PA, Mathias CJ, Poewe W, Wenning GK (2007) Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 14:66-72
56. Kollensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Ostergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK (2008) Red flags for multiple system atrophy. Mov Disord 23:1093-1099
57. Kollensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK (2010) Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 25:2604-2612
58. Kollensperger M, Krismer F, Pallua A, Stefanova N, Poewe W, Wenning GK (2011) Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Mov Disord 26:507-515
59. Lee JE, Song SK, Hong JY, Sunwoo MK, Park HJ, Sohn YH, Lee PH (2013) Changes in the blood-brain barrier status closely correlate with the rate of disease progression in patients with multiple system atrophy: a longitudinal study. Parkinsonism Relat Disord 19: 450-452
60. Lees AJ, Bannister R (1981) The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). J Neurol Neurosurg Psychiatry 44:347-351
61. Lezcano E, Gomez-Esteban JC, Zarranz JJ, Alcaraz R, Atares B, Bilbao G, Garibi J, Lambarri I (2004) Parkinson’s disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report. Mov Disord 19:973-977
62. Li J, Zhu M, Rajamani S, Uversky VN, Fink AL (2004) Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11:1513-1521
63. Low PA, Gilman S (2012) Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Ann Neurol 72:4-5
64. Low P, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser R, Cheshire W, Lessig S, Vernino S, Mandreak J, Dupont W, Chelimsky T, Galpern W (2013) Randomized treatment trial of Rifampicin in MSA patients. Abstracts of the XVII international congress of Parkinson’s disease and other movement disorders, 2013. Sydney, Australia. Mov Dis 28(Suppl 1):S149
65. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685-688
66. Mathias CJ (2008) L-Dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 18(Suppl 1):25-29
67. Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD (2001) l-Threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 11:235-242
68. Mazza A, Ravenni R, Antonini A, Casiglia E, Rubello D, Pauletto P (2013) Arterial hypertension, a tricky side of Parkinson’s disease: physiopathology and therapeutic features. Neurol Sci 34:621-627
69. McCrone P, Payan CA, Knapp M, Ludolph A, Agid Y, Leigh PN, Bensimon G (2011) The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom. PLoS One 6:e24369
70. Mehanna R, Jankovic J (2010) Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord 16:628-638
71. Merlo IM, Occhini A, Pacchetti C, Alfonsi E (2002) Not paralysis, but dystonia causes stridor in multiple system atrophy. Neurology 58:649-652
72. Mostile G, Jankovic J (2009) Treatment of dysautonomia associated with Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3):S224-S232
73. Muller J, Wenning GK, Wissel J, Seppi K, Poewe W (2002) Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249:300-304
74. Nonaka M, Imai T, Shintani T, Kawamata M, Chiba S, Matsumoto H (2006) Non-invasive positive pressure ventilation for laryngeal contraction disorder during sleep in multiple system atrophy. J Neurol Sci 247:53-58
75. Oettle GJ (1991) Effect of moderate exercise on bowel habit. Gut 32:941-944
76. Ono K, Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97:105-115
77. Ozawa T, Sekiya K, Sekine Y, Shimohata T, Tomita M, Nakayama H, Aizawa N, Takeuchi R, Tokutake T, Katada S, Nishizawa M (2012) Maintaining glottic opening in multiple system atrophy: efficacy of serotonergic therapy. Mov Disord 27:919-921
78. Park HJ, Bang G, Lee BR, Kim HO, Lee PH (2011) Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transplant 20:827-835
79. Pathak A, Raoul V, Montastruc JL, Senard JM (2005) Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol 61:471-474
80. Plaschke M, Trenkwalder P, Dahlheim H, Lechner C, Trenkwalder C (1998) Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson’s Disease and multiple system atrophy. J Hypertension 16(10):1433-1441
81. Podoleanu C, Maggi R, Brignole M, Croci F, Incze A, Solano A, Puggioni E, Carasca E (2006) Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol 48:1425-1432
82. Poewe W, Barone P, Giladi N, Gilman S, Low P, Sampaio C, Seppi K, Wenning GK, for the “Rasagiline for MSA Investigators” (2012) A randomized, placebo-controlled clinical trial to assess the effects of Rasagiline in patients with multiple system atrophy of the parkinsonian type. Abstracts of the sixteenth international congress of Parkinson’s disease and movement disorders, 2012. Dublin, Ireland. Mov Disord 27(Suppl 1):S390.
83. Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Ivanova MI, Loo JA, Klarner FG, Schrader T, Stahl M, Bitan G, Bronstein JM (2012) A novel “molecular tweezer” inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 9:464-476
84. Rack MJ, Baran AS, Richert AC, Roffwarg HP (2004) Cardiopulmonary complications of ergot-derivative dopamine agonists. J Clin Psychiatry 65:1429-1430, author reply 1430
85. Sacca F, Marsili A, Quarantelli M, Brescia Morra V, Brunetti A, Carbone R, Pane C, Puorro G, Russo CV, Salvatore E, Tucci T, De Michele G, Filla A (2013) A randomized clinical trial of lithium in multiple system atrophy. J Neurol 260:458-461
86. Sakakibara R, Murakami E, Katagiri A, Hayakawa S, Uchiyama T, Yamamoto T, Hattori T (2007a) Moxibustion, an alternative therapy, ameliorated disturbed circadian rhythm of plasma arginine vasopressin and urine output in multiple system atrophy. Intern Med 46:1015-1018
87. Sakakibara R, Yamaguchi T, Uchiyama T, Yamamoto T, Ito T, Liu Z, Odaka T, Yamaguchi C, Hattori T (2007b) Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord 22:1672-1673
88. Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T (2011) Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinsons Dis 2011: 605-924
89. Santens P, Vonck K, de Letter M, van Driessche K, Sieben A, de Reuck J, van Roost D, Boon P (2006) Deep brain stimulation of the internal pallidum in multiple system atrophy. Parkinsonism Relat Disord 12:181-183
90. Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, Kollensperger M, Scherfler C, Quinn N, Pellecchia MT, Barone P, del Sorbo F, Albanese A, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Nilsson CF, Widner H, Lindvall O, Giladi N, Gurevich T, Daniels C, Deuschl G, Coelho M, Sampaio C, Abele M, Klockgether T, Schimke N, Eggert KM, Oertel W, Djaldetti R, Colosimo C, Meco G, Poewe W, Wenning GK (2006) Health-related quality of life in multiple system atrophy. Mov Disord 21:809-815
91. Schrag A, Sheikh S, Quinn NP, Lees AJ, Selai C, Mathias C, Litvan I, Lang AE, Bower JH, Burn DJ, Low P, Jahanshahi M (2010) A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 25:1077-1081
92. Seppi K, Hogl B, Diem A, Peralta C, Wenning GK, Poewe W (2006) Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. Mov Disord 21:1281-1283
93. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42-S80
94. Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, Robertson D, Biaggioni I (2006) Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension 47:522-526
95. Shibao C, Lipsitz LA, Biaggioni I (2013) ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich) 15:147-153
96. Shioda K, Nisijima K, Kato S (2006) Electroconvulsive therapy for the treatment of multiple system atrophy with major depression. Gen Hosp Psychiatry 28:81-83
97. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA (2003) Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 74:1294-1298
98. Smit AA, Wieling W, Fujimura J, Denq JC, Opfer-Gehrking TL, Akarriou M, Karemaker JM, Low PA (2004) Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res 14:167-175
99. Song IU, Kim JS, Lee KS (2008) Dopa-responsive camptocormia in a patient with multiple system atrophy. Parkinsonism Relat Disord 14:161-163
100. Staessen JA, Asmar R, de Buyzere M, Imai Y, Parati G, Shimada K, Stergiou G, Redon J, Verdecchia P (2001) Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit 6:355-370
101. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S (2012) Latrepirdine stimulates autoph-agy and reduces accumulation of alpha-synuclein in cells and in mouse brain. Mol Psychiatry. doi:10.1038/mp.2012.115
102. Stefanova N, Reindl M, Poewe W, Wenning GK (2005a) In vitro models of multiple system atrophy. Mov Disord 20(Suppl 12):S53-S56
103. Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK (2005b) Animal models of multiple system atrophy. Trends Neurosci 28:501-506
104. Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK (2007) Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 22:2196-2203
105. Suzuki K, Okada K, Wakuda T, Shinmura C, Kameno Y, Iwata K, Takahashi T, Suda S, Matsuzaki H, Iwata Y, Hashimoto K, Mori N (2010) Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine. PLoS One 5:e9260
106. Takei A, Hamada S, Homma S, Hamada K, Tashiro K, Hamada T (2010) Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. Cerebellum 9:567-570
107. Thobois S, Brousolle E, Toureille L, Vial C (2001) Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. Mov Dis 16(4):764-765
108. Tison F, Yekhlef F, Chrysostome V (2006) Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson’s disease. Mov Disord 21: 1056-1057
109. Todorova A, Vonderheid-Guth B, Dimpfel W (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41:636-644
110. Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, Shults C, Masliah E (2008) Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 19:1271-1276
111. Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, Rockenstein E, May V, Winkler J, Masliah E (2012) Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp Neurol 234:405-416
112. Ullman M, Vedam-Mai V, Resnick AS, Yachnis AT, McFarland NR, Merritt S, Zeilman P, Foote KD, Okun MS (2012) Deep brain stimulation response in pathologically confirmed cases of multiple system atrophy. Parkinsonism Relat Disord 18:86-88
113. van Leeuwen RB, Perquin WV (1988) Bromocriptine therapy in striatonigral degeneration. J Neurol Neurosurg Psychiatry 51:592
114. Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, De Bie RM, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Ostergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzicka E, Samuel M, Speelman H, Sydow O, Valldeoriola F, Van Der Linden C, Oertel W (2013) Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review. J Neurol, Jan 5. Epub ahead of print
115. Wedge F (2008) The impact of resistance training on balance and functional ability of a patient with multiple system atrophy. J Geriatr Phys Ther 31:79-83
116. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M (2010) The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6(202-211):e7
117. Wenning GK (2005) Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol 28:225-227
118. Wenning GK, Fanciulli A (2013) Dysautonomia in movement disorders. In: Jankovic J, Poewe W (ed) Movement disorders in neurologic and systemic disease. Cambridge Uni Press, in press.
119. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12:133-147
120. Wenning GK, Geser F, Poewe W (2005) Therapeutic strategies in multiple system atrophy. Mov Disord 20(Suppl 12):S67-S76
121. Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Kollensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12:264-274
122. Winter Y, Stamelou M, Cabanel N, Sixel-Doring F, Eggert K, Hoglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE (2011) Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol 258:1827-1834
123. Young TM, Mathias CJ (2004) The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry 75:1737-1741
124. Z’Graggen WJ, Hess CW, Humm AM (2010) Acute fluid ingestion in the treatment of orthostatic intolerance - important implications for daily practice. Eur J Neurol 17:1370-1376
125. Ziegler MG, Milic M (2012) New therapies for postural hypotension. Hypertension 59:548-549